Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
PHENYTOIN SODIUM
Pfizer Healthcare Ireland
N03AB; N03AB02
PHENYTOIN SODIUM
100 milligram(s)
Capsule, hard
Product subject to prescription which may be renewed (B)
Hydantoin derivatives; phenytoin
Marketed
1979-04-01
Page 1 of 8 2020-0062933 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT EPANUTIN ® 100 MG HARD CAPSULES (PHENYTOIN SODIUM) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Epanutin Hard Capsules are and what they are used for 2. What you need to know before you take Epanutin 3. How to take Epanutin 4. Possible side effects 5. How to store Epanutin 6. Contents of the pack and other information 1. WHAT EPANUTIN HARD CAPSULES ARE AND WHAT THEY ARE USED FOR This medicine contains phenytoin, which is one of a group of medicines called anti-epileptic drugs; these medicines are used to treat epilepsy. Epanutin can be used to control a variety of epileptic conditions, to control or prevent seizures during or after brain surgery or severe head injury. Epanutin can also be used to treat trigeminal neuralgia (facial nerve pain). You should ask your doctor if you are unsure why you have been given Epanutin Capsules, if you do not feel better or if you feel worse. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE EPANUTIN DO NOT TAKE EPANUTIN if you are allergic (hypersensitive) to phenytoin, or any of the other ingredients of this medicine (listed in section 6) if you are allergic to other medicines for epilepsy if you are taking medicines for HIV infection, such as delavirdine. _ _ WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before you take Epanutin if you suffer from or have suffered in the past from any of the following conditions: Liver disease Kidney disease Porphyri Read the complete document
Health Products Regulatory Authority 27 January 2021 CRN00C4Q5 Page 1 of 14 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Epanutin 100 mg Hard Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains phenytoin sodium 100 mg Excipient with known effect Each capsule contains 96.15 mg lactose monohydrate For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Capsules, hard. A white powder in a No. 3 hard gelatin capsule with a white opaque body and orange cap, radially imprinted ‘EPANUTIN 100’. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Control of tonic-clonic seizures (grand mal epilepsy), partial seizures (focal including temporal lobe) or a combination of these, and for the prevention and treatment of seizures occurring during or following neurosurgery and/or severe head injury. Epanutin has also been employed in the treatment of trigeminal neuralgia but it should only be used as second line therapy if carbamazepine is ineffective or patients are intolerant to carbamazepine. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For oral administration only. _Dosage:_ Dosage should be individualised as there may be wide interpatient variability in phenytoin serum levels with equivalent dosage. Epanutin should be introduced in small dosages with gradual increments until control is achieved or until toxic effects appear. In some cases serum level determinations may be necessary for optimal dosage adjustments - the clinically effective level is usually 10 mcg/ml–20 mcg/ml (40-80 micromoles/l) although some cases of tonic-clonic seizures may be controlled with lower serum levels of phenytoin. With recommended dosage a period of seven to 10 days may be required to achieve steady state serum levels with Epanutin and changes in dosage should not be carried out at intervals shorter than 7 to ten days. Maintenance of treatment should be the lowest dose of anticonvulsant consistent with control of seizures. _Epanutin Capsules, Suspension and Infatabs:_ Epanutin Capsule Read the complete document